Annual report
7459.TEDINET S100W5ET
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.67T | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥3.56T | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥3.36T | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.29T | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.21T | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥55.6bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥47.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥65.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥64.6bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥65.1bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥62.0bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥53.0bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥76.7bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥74.7bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥40.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥41.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥38.8bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥29.4bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥23.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥51.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥51.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥1.82T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.80T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.71T | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.71T | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.68T | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.07T | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.06T | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥757.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥736.6bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥688.1bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥649.1bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥638.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥261.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥230.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥259.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥228.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥193.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥260.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥240.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥60.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥61.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥61.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥34.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥3.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥39.5bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥24.3bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥25.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥25.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥43.5bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥16.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥16.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥193.2 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.83 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥184.82 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.14 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥113.96 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥179.12 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥131.41 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥106.8 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2,979.39 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,858.57 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,673.62 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,525.72 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,490.98 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 33.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.4% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.8% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.0% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.1% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.6% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.6% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 13,061 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 13,075 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 12,795 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 12,801 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 12,971 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥30.4bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue2 |
| Revenue | ¥30.3bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue2 |
| Revenue | ¥33.0bn | 2022-04-01 → 2023-03-31d | Standalone | Operating revenue2 (5-year summary) |
| Revenue | ¥26.6bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue2 (5-year summary) |
| Revenue | ¥28.3bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue2 (5-year summary) |
| Operating income | ¥19.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥12.9bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥20.5bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥14.1bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥18.2bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.9bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥19.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥23.8bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥23.4bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥20.8bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥21.1bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥21.4bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.8bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥20.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥368.8bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥368.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥355.4bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥373.6bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥386.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥23.7bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥22.4bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥345.1bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥345.7bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥333.6bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥321.0bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥327.4bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥35.6bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥21.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥99.58 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.55 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥102.07 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.99 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥98.75 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥98.81 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥56.93 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥92.49 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥62 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥46 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥44 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥42 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,659.45 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,646.21 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,588.95 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,528.64 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,559.37 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 93.6% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.9% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.9% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.7% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.0% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 219,226,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 221,291,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 225,463,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 244,524,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 244,524,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 185 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 183 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 173 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 173 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 169 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥148m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥41m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥3.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥3.9bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥38.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥50m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥702m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | employees | at 2025-03-31 | 746 pure |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥116.9bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥116.9bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥2m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment assets | at 2025-03-31 | ¥83.0bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥2.4bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥6.5bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | employees | at 2025-03-31 | 2283 pure |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.19T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.19T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥345m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2025-03-31 | ¥503.6bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥28.0bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥11.5bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥8.6bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | employees | at 2025-03-31 | 9836 pure |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.37T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.37T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2025-03-31 | ¥1.20T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥25.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥14.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥3.68T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥3.67T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥1.79T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥55.7bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥153m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥114m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥3.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥3.1bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥24.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥41m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥472m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥114.0bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥114.0bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment assets | at 2024-03-31 | ¥87.3bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥6.5bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.15T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.15T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥306m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2024-03-31 | ¥492.5bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥27.2bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥18.2bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥8.5bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.30T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.29T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2024-03-31 | ¥1.19T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥20.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥16.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥3.56T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥3.56T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥1.77T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥47.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,069
| Item | Context | Value | Unit |
|---|---|---|---|
| Audit fees total | CurrentYearDuration | 333000000 | JPY |
| Non audit fees total | CurrentYearDuration | － | JPY |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 281000000 | JPY |
| Fixed remuneration remuneration by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 192000000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 88000000 | JPY |
| Retirement benefits remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | － | JPY |
| Non monetary remuneration remuneration by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 8 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 45000000 | JPY |
| Fixed remuneration remuneration by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 45000000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | － | JPY |
| Retirement benefits remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | － | JPY |
| Non monetary remuneration remuneration by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 2 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsMember | 57000000 | JPY |
| Fixed remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideDirectorsMember | 57000000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideDirectorsMember | － | JPY |
| Retirement benefits remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsMember | － | JPY |
| Non monetary remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideDirectorsMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsMember | 4 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideCorporateAuditorsMember | 32000000 | JPY |
| Fixed remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideCorporateAuditorsMember | 32000000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideCorporateAuditorsMember | － | JPY |
| Retirement benefits remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideCorporateAuditorsMember | － | JPY |
| Non monetary remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideCorporateAuditorsMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideCorporateAuditorsMember | 3 | |
| Number of issues shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 21 | |
| Carrying amount shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 3171000000 | JPY |
| Number of issues shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 46 | |
| Carrying amount shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 92245000000 | JPY |
| Number of issues whose number of shares increased shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Total acquisition cost for increased shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | JPY |
| Number of issues whose number of shares increased shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | 5 | |
| Total acquisition cost for increased shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | 229000000 | JPY |
| Number of issues whose number of shares decreased shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | 2 | |
| Total sale amount for decreased shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | 64000000 | JPY |
| Number of issues whose number of shares decreased shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | 4 | |
| Total sale amount for decreased shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | 11850000000 | JPY |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | 5316000 | |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row1Member | 6148000 | |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | 41214000000 | JPY |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row1Member | 38793000000 | JPY |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | 2570089 | |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row2Member | 3230089 | |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | 9023000000 | JPY |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row2Member | 15430000000 | JPY |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | 2192968 | |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row3Member | 1096484 | |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | 6133000000 | JPY |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row3Member | 5984000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |